SCHEMBL7337667

SCHEMBL7337667

CC(C)(C)[Si](C)(COCc1ccc(N)cc1)O[Si](C)(COCc1ccc(N)cc1)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.35
APP P05067 1/20 0.34
ALDH1A1 P00352 2/20 0.33
GFER P55789 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MAPT P10636 3/20 0.33
RAB9A P51151 3/20 0.33
GAA P10253 1/20 0.33
MAOA P21397 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.32
CYP19A1 P11511 2/20 0.31
LMNA P02545 1/20 0.31
NPC1 O15118 2/20 0.30
HPGD P15428 1/20 0.30
MAPK1 P28482 1/20 0.30
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6598260 0.76 GFER (0.45) MAOBALDH1A1GFERCYP3A4TSHR
SCHEMBL7337658 0.73 MAOB (0.35) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL133816 0.72 MAOB (0.39) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL234606 0.71 ALDH1A1 (0.55) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL11367135 0.68 TSHR (0.48) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL4301097 0.67 TSHR (0.50) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL4302217 0.67 TSHR (0.50) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL1491341 0.66 TSHR (0.44) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL11957416 0.66 ALDH1A1 (0.44) MAOBAPPALDH1A1GFERCYP3A4
SCHEMBL18217416 0.66 ALDH1A1 (0.44) MAOBAPPALDH1A1GFERCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 MAOB 666/4885APP 3852/4885ALDH1A1 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.